Dietary Fiber: A Natural Ally in Reducing Radiation Toxicity for Pelvic Cancer Patients

High-Fiber Diet During Radiation Therapy for Pelvic Cancer

Study Overview

A recent study has revealed that a high-fiber diet during radiation therapy for pelvic cancer significantly reduces gastrointestinal radiation toxicity, both in the short and long term, compared to a habitual fiber intake. This finding challenges the traditional recommendation of low-fiber diets for patients undergoing pelvic radiation therapy.

Background on Radiation Therapy

Radiation therapy is a common treatment for abdominal and pelvic cancers. However, many patients experience changes in bowel habits due to mucosal injury and inflammation caused by the treatment. Some may develop chronic intestinal dysfunction resulting from vascular sclerosis and transmural fibrosis. Historically, clinicians have advised low-fiber diets during this therapy, yet there has been no substantial evidence to support this practice.

Previous Research Limitations

Previous studies investigating the relationship between dietary fiber and radiation-induced injury have produced inconclusive results, leading to ongoing uncertainty in dietary recommendations for these patients.

Details of the Recent Study

Published in the *American Journal of Clinical Nutrition*, the study assessed the impact of dietary fiber on gastrointestinal toxicity related to radiation therapy for pelvic cancer. Patients were recruited from the Royal Marsden NHS Foundation Trust and the Royal Surrey County Hospital in England. The study included 166 patients with gastrointestinal or gynecological cancer scheduled for radiation therapy.

Patient Grouping and Methodology

Participants were divided into three groups based on their fiber intake: a high-fiber diet group (≥ 18 grams of nonstarch polysaccharide per day), a habitual diet control group, and a low-fiber diet group (≤ 10 grams of nonstarch polysaccharide per day). All patients received the same radiation dosage over a period of 5 to 7 weeks. To evaluate gastrointestinal toxicity, researchers scored the severity of bowel symptoms at baseline, weekly during treatment, and one year post-treatment using the Inflammatory Bowel Disease Questionnaire (IBDQ) and its bowel subset (IBDQ-B), with lower scores indicating more severe symptoms.

Findings of the Study

At the baseline, there were no significant differences in IBDQ-B scores among the three groups. However, all groups experienced an increase in bowel symptoms during radiation treatment. Notably, the decline in IBDQ-B scores from the start to the end of therapy was less pronounced in the high-fiber group compared to the habitual-fiber group. After one year, the high-fiber group’s scores returned to baseline levels, while the habitual-fiber group did not exhibit the same recovery.

Furthermore, the IBDQ scores showed a significant reduction from the start to the end of therapy in the habitual-fiber group, while the high-fiber group demonstrated only a marginal decline, suggesting an improvement in patient well-being over time.

Other Measurements

The study also assessed stool frequency, stool form, and fecal concentrations of short-chain fatty acids, but no significant differences were observed among the three groups.

Study Limitations

A limitation of the study was the lack of consideration for variables such as smoking, medication, prior surgeries, or pre-existing inflammatory conditions, which could potentially influence the outcomes.

Conclusions and Recommendations

The study’s findings indicate that a high-fiber diet may offer benefits in alleviating gastrointestinal toxicity following radiotherapy for pelvic cancer. Consequently, the authors recommend that healthcare providers reconsider the standard advice of low-fiber diets for patients undergoing this treatment.

Written by

Usha B. Nair, Ph.D.

References

1. Shadad AK, Sullivan FJ, Martin JD, Egan LJ. Gastrointestinal radiation injury: symptoms, risk factors and mechanisms. World J Gastroenterol. 2013 Jan 14;19(2):185-98. doi: 10.3748/wjg.v19.i2.185.
2. Lodge N, Evans ML, Wilkins M, Blake PR, Fryatt I. A randomized cross-over study of the efficacy of codeine phosphate versus Ispaghulahusk in patients with gynaecological cancer experiencing diarrhoea during pelvic radiotherapy. Eur J Cancer Care (Engl). 1995 Mar;4(1):8-10.
3. Murphy J, Stacey D, Crook J, Thompson B, Panetta D. Testing control of radiation-induced diarrhea with a psyllium bulking agent: a pilot study. Can Oncol Nurs J. 2000 Summer;10(3):96-100.
4. Pettersson A, Johansson B, Persson C, Berglund A, Turesson I. Effects of a dietary intervention on acute gastrointestinal side effects and other aspects of health-related quality of life: a randomized controlled trial in prostate cancer patients undergoing radiotherapy. Radiother Oncol. 2012 Jun;103(3):333-40. doi: 10.1016/j.radonc.2012.04.006.
5. Salminen E, Elomaa I, Minkkinen J, Vapaatalo H, Salminen S. Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. Clin Radiol. 1988 Jul;39(4):435-7.
6. Wedlake L, Shaw C, McNair H, et al. Randomized controlled trial of dietary fiber for the prevention of radiation-induced gastrointestinal toxicity during pelvic radiotherapy. Am J Clin Nutr. 2017 Jul 5. doi: 10.3945/ajcn.116.150565.